A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

Inclusion Criteria: * Clinical diagnosis of nonsegmental vitiligo with genital involvement * At least ≥ 0.25% BSA of nonsegmental vitiligo in the genital area. * Pigmented hair within some of the genital vitiligo areas. * At least 1 genital target lesion that is ≥ 0.1% BSA that has a pigmented hair within it. * Vitiligo on areas of the body besides the genitals. * Total body vitiligo area not exceeding 10% BSA. * Willing to have genital photography conducted. * Must agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted. Exclusion Criteria: * Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders. * Prior or current use of depigmentation treatments (eg, monobenzone). * Active or recurrent genital warts or herpes. * Male participants with partners with known current/active cervical intraepithelial neoplasia or anal intraepithelial neoplasia. * An active sexually transmitted disease, sexually transmitted infection, or other skin disorder affecting the genital area (eg, scabies, fungal infection, molluscum). * Had ≥ 3 laser hair removal treatments in an area to be treated for vitiligo. * Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study or interpretation of study data. * Clinical laboratory test results outside of protocol defined ranges * Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.